Medical Oncology

Kathleen Ann Cooney, MD

Professor of Medicine
Chair, Department of Medicine
Member of the Duke Cancer Institute
Campus mail 2301 Erwin Road Suite 1102, DUMC 3703, Durham, NC 27710
Phone (919) 681-2452
Email address kathleen.cooney@duke.edu

Dr. Cooney is Chair of the Duke Department of Medicine.

She is a medical oncologist focused in caring for men with prostate cancer, and is internationally known for her investigations focused on the genetic epidemiology of prostate cancer.

Her research led to the important discovery of a recurrent mutation in the HOXB13 gene that increases the chances of being diagnosed with prostate cancer and is estimated to account for 5 percent of hereditary prostate cancer cases worldwide. Since men with HOXB13 mutations are at an increased risk of prostate cancer, they may benefit from participation in screening and potentially prevention protocols in the future.

Dr. Cooney’s research continues with federal funding to identify germline mutations associated with lethal and aggressive prostate cancer as well as prostate cancer in African American men.

Education and Training

  • Fellow, Hematology / Oncology, University of Michigan at Ann Arbor, 1988 - 1991
  • Chief Medical Resident, Internal Medicine, University of Michigan at Ann Arbor, 1987 - 1988
  • Intern/Resident, Internal Medicine, University of Michigan at Ann Arbor, 1984 - 1987
  • M.D., University of Pennsylvania School of Medicine, 1984

Grants

Publications

Jalali, Ali, Christopher Martin, Richard E. Nelson, Megan E. Vanneman, Brook I. Martin, Kathleen A. Cooney, Norman J. Waitzman, and Brock O’Neil. “Provider Practice Competition and Adoption of Medicare's Oncology Care Model.” Med Care 58, no. 2 (February 2020): 154–60. https://doi.org/10.1097/MLR.0000000000001243.

PMID
31688568
Full Text

Wu, Yishuo, Hongjie Yu, Shuwei Li, Kathleen Wiley, S Lilly Zheng, Holly LaDuca, Marta Gielzak, et al. “Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer.” Eur Urol Oncol, January 13, 2020. https://doi.org/10.1016/j.euo.2019.12.003.

PMID
31948886
Full Text

Boyle, Julie, and Kathleen A. Cooney. “DNA repair genes: contributions to prostate cancer predisposition and aggressiveness.” Can J Urol 26, no. 5S2 (October 2019): 10–11.

PMID
31629416
Scholars@Duke

Isaacs, William B., Kathleen A. Cooney, and Jianfeng Xu. “Updated insights into genetic contribution to prostate cancer predisposition: focus on HOXB13.” Can J Urol 26, no. 5S2 (October 2019): 12–13.

PMID
31629417
Scholars@Duke

Beebe-Dimmer, Jennifer L., Julie J. Ruterbusch, Kathleen A. Cooney, Adam Bolton, Kendra Schwartz, Ann G. Schwartz, and Elisabeth Heath. “Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER-Medicare investigation.” Cancer Med 8, no. 6 (June 2019): 3325–35. https://doi.org/10.1002/cam4.2092.

PMID
31094098
Full Text

Mara, Alexandria, Jason Zhu, Yuan Wu, Tom Callis, Shan Yang, Edward D. Esplin, Robert L. Nussbaum, et al. “Prevalence of pathogenic germline variants in DNA repair by race, age, and ethnicity in men with prostate cancer.” In Journal of Clinical Oncology, 37:5062–5062. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.5062.

Full Text

Beebe-Dimmer, Jennifer L., and Kathleen A. Cooney. “Mitochondrial alterations may underlie race-specific differences in cancer risk and outcome.” J Clin Invest 129, no. 6 (May 6, 2019): 2187–88. https://doi.org/10.1172/JCI128707.

PMID
31063989
Full Text

Cooney, Kathleen A., and Jennifer L. Beebe-Dimmer. “Finding a Needle in the Haystack: The Search for Germline Variants Associated with Prostate Cancer Clinical Outcomes.” Eur Urol 74, no. 6 (December 2018): 720–21. https://doi.org/10.1016/j.eururo.2018.07.001.

PMID
30029823
Full Text

Wu, Yishuo, Hongjie Yu, Siqun Lilly Zheng, Bingjian Feng, Ashley L. Kapron, Rong Na, Julie L. Boyle, et al. “Germline mutations in PPFIBP2 are associated with lethal prostate cancer.” Prostate 78, no. 16 (December 2018): 1222–28. https://doi.org/10.1002/pros.23697.

PMID
30043417
Full Text

Hahn, A. W., A. L. Kapron, J. Boyle, W. Kohlmann, A. Poole, D. M. Gill, S. Greenberg, et al. “Prevalence of clinically actionable germline pathogenic variants (PVs) in advanced prostate cancer (aPC).” Annals of Oncology : Official Journal of the European Society for Medical Oncology 29 (October 1, 2018): viii294. https://doi.org/10.1093/annonc/mdy284.050.

Full Text

Pages